Solutions for Newborn screening
Fatty Acid Oxidation Disorders

Carnitine Uptake Defect (CUD)

background

background

Carnitine uptake defect (CUD) is a condition that prevents the body from using fats for energy, particularly during periods without food (fasting). Carnitine, a natural substance acquired mostly through diet, is used by cells to process fats and produce energy. In people with CUD, proteins called carnitine transporters do not work properly. These proteins normally bring carnitine into cells and prevent the escape of carnitine from the body in urine. CUD is estimated to occur in less than 1 of 100 000 live births. However it has been reported to have an incidence rate of 1:40 000 live births in Japan.

clinical

clinical

Typically, initial signs and symptoms of this disorder occur during infancy or early childhood and often include changes in brain tissue (encephalopathy) resulting in functional abnormalities; an enlarged, poorly pumping heart (cardiomyopathy); confusion; vomiting; muscle weakness; and low blood sugar (hypoglycemia). Serious complications such as heart failure, liver problems, coma, and sudden unexpected death are also a risk. Severe illness due to CUD can be triggered by periods of fasting or illnesses such as viral infections, particularly when eating is reduced.

This condition is sometimes mistaken for Reye syndrome, a severe disorder that develops in children while they appear to be recovering from viral infections such as chicken pox or flu.

testing

testing

Newborn screening using tandem mass spectrometry of a dried blood spot identifies low level of free carnitine (C0). (C0+C2+C3+C16+C18:1+C18)/Cit is also found as informative ratio. Plasma and urine carnitine analysis will reveal decreased free and total carnitine (C0) in plasma and overexcretion of carnitine in urine. The newborn’s mother should be investigated, as well, because several cases of maternal CUD have been identified following an abnormal newborn screening result in their offspring. Transporter assays and OCTN2 gene sequencing establish the diagnosis.

treatment

treatment

Treating CUD patients with oral L-carnitine supplementation is followed by a slow increase of plasma carnitine levels. If the infants’ levels reflect maternal primary carnitine deficiency, the rise in plasma levels is fast and this should prompt the work-up towards the diagnosis of maternal primary carnitine deficiency. CUD patients should also avoid fasting and sometimes low-fat, high carbonhydrate diet is used in addition to L-carnitine. Guidelines for the management of carnitine deficiency and other fatty acid mitochondrial disorders have been established.

Because the diagnosis and therapy of CUD is complex, the pediatrician is advised to manage the patient in close collaboration with a consulting pediatric metabolic disease specialist. It is recommended that parents travel with a letter of treatment guidelines from the patient’s physician.

inheritance

inheritance

This disorder follows an autosomal recessive inheritance pattern. With recessive disorders affected patients usually have two copies of a disease gene (or mutation) in order to show symptoms. People with only one copy of the disease gene (called carriers) generally do not show signs or symptoms of the condition but can pass the disease gene to their children. When both parents are carriers of the disease gene for a particular disorder, there is a 25% chance with each pregnancy that they will have a child affected with the disorder.


Related instruments

Related kits

Source: Newborn Screening Today (2011), PerkinElmer Inc., Waltham MA

Related articles

Presentation

China reaching >95% Coverage - now undergoing a Panel Expansion

China NBS program formally started in 1983, even small pilot study since 1981.During the past 35 years, China has achieved great progress in newborn screening, no matter in uptake rate but also in expanding screening program. By 2017, overall uptake rate for CH and PKU screening was >96%. This is a great number if you take the newborn number in China is 17 M every year. Currently CH/PKU and hearing loss are included as national wide screening program, which is also mandatory for all newborn.
Presentation

First years of experience on LSD screening in Italy, Padova

The increasing availability of treatments and the importance of early inter- vention have stimulated newborn screening (NBS) for lysosomal storage dis- eases (LSDs). We present our experience screening newborns in North East Italy to identify neonates with Mucopolysaccharidosis type I (MPS I) and Pompe, Fabry, and Gaucher diseases.
Presentation

Cooperation between the private and public sectors in Jordan

The field of Newborn Screening (NBS) has come a long way since the days of Dr. Guthrie and the introduction of PKU screening in the 1960s. Most developed countries now have expanded NBS programs covering a range of disorders, many of which are population based. In many developing coun- tries, due to a number of factors, the role of expanded NBS programs is often left to the private sector and for those who can afford to pay for the test.

Presentation

High risk screening of MPS disorders (MSPII,III,IVa...)

Introduction: Lysosomal storage disorders (LSD’s) are a group of more than 40 disorders caused by the specific deficiency of enzymes (& co-factors) within the lysosome. This leads to the accumulation of substrates, lipids, sphingolipids and mucopolysaccharides resulting in organelle and cellular dysfunction and the pathology in the LSD’s. The estimated incidence has been determined to be as high as 1 in 7,000 in the Australian population (1), even higher in certain ethic groups.
Regional report

Some Governments need pushing for NBS in Middle East and North Africa

“Newborn screening is not simply buying a kit or a machine; it’s a whole approach of analysis and interpretation. Now, it’s time to convince the authorities to move forward”, says Dr. Issam Khneisser, NBS pioneer in the Middle East and North Africa (MENA) region.
Presentation

Expansion of the Dutch neonatal Screening Programme. Policy and Practice

In this presentation, the carefully crafted approach of shaping the innovation of the Dutch neonatal screening program is covered.
News

PerkinElmer Genetics Launches New LSD Testing Service

PerkinElmer® Genetics, located just outside of Pittsburgh, Pennsylvania, has been providing newborn screening services for over 20 years. During that time, the laboratory has processed close to six million samples using biochemical, molecular and mass spec based technology while partnering with the states of Pennsylvania, Mississippi, Nebraska, Louisiana and the District of Columbia. In 2010, PerkinElmer Genetics started offering a 6-plex assay to test for Gaucher, Niemann-Pick, Krabbe, Hurler-MPS-I, Pompe and Fabry lysosomal storage disorders. More recently, they completed the development and validation of tests for MPS-IVA and VI. Work is also underway to add testing for Adrenoleukodystrophy (X-ALD) with the goal to being able to offer all these tests as part of their StepOne® Newborn Screening, a “Lab in a Lab” or as back-up testing for labs that experience unplanned outages. For more information, please contact PJ Borandi at PJ.Borandi@PerkinElmer.com.
Regional report

Regional news: A report from North America

Newborn screening (NBS) expansion is once again gaining momentum in the United States with many disorders being considered due to promising new treatments, better testing methods and other factors that impact the decision making process. Three factors that have helped shape the NBS landscape in the U.S.
Interview

Taiwan on the forefront of implementing new disorders

Dr. Yin-Hsiu Chien, director of the newborn screening center at the National Taiwan University Hospital, has made diverse contributions in the field of inborn errors of metabolism and immunodeficiency. Her team, lead by Dr Wuh-Lang Hwu is devoted to the diagnosis and treatment of lysosymal storage diseases (LSD). Dr. Chien’s current work focuses on Pompe disease, specifically on early diagnosis and improvement of treatment. Dr. Chien and her team have played an important role in making Taiwan’s newborn screening programs into one of the most developed newborn screening programs in the world.

Presentation

NBS panel expansion in the Philippines, Maria Melanie Liberty B. Alcausin, MD, Philippines

The NBS Program in the Philippines started out as a pilot project involving 24 hospitals in the country’s capital region. It took some time for the newborn screening program to be successfully integrated into the national health program through the Philippine Newborn Screening Act of 2004. Almost two decades after the pilot project, the program was deemed ready for the expansion from screening for six disorders to screening for more than 20 disorders. The presentation from Dr. Melanie presents the challenges of implementing an expanded newborn screening program in a developing country like the Philippines and the conditions identified in the first phases of offering the service.
This website stores cookies on your computer. These cookies are used to improve our website and provide more personalised services to you.
To find out more about cookies, please click here
Close

Cookies

To make this site work properly, we sometimes place small data files called cookies on your device. Most big websites do this too.

1. What are cookies?

A cookie is a small text file that a website saves on your computer or mobile device when you visit the site. It enables the website to remember your actions and preferences (such as login, language, font size and other display preferences) over a period of time, so you don’t have to keep re-entering them whenever you come back to the site or browse from one page to another.

2. How do we use cookies?

A number of our pages use cookies to remember your actions and preferences (such as login, language, font size and other display preferences.)

Also, some videos embedded in our pages use a cookie to anonymously gather statistics on how you got there and what videos you visited.

Enabling these cookies is not strictly necessary for the website to work but it will provide you with a better browsing experience. You can delete or block these cookies, but if you do that some features of this site may not work as intended.

The cookie-related information is not used to identify you personally and the pattern data is fully under our control. These cookies are not used for any purpose other than those described here.

3. How to control cookies

You can control and/or delete cookies as you wish – for details, see aboutcookies.org. You can delete all cookies that are already on your computer and you can set most browsers to prevent them from being placed. If you do this, however, you may have to manually adjust some preferences every time you visit a site and some services and functionalities may not work.

Close